{
    "clinical_study": {
        "@rank": "75501", 
        "acronym": "ROTATE", 
        "arm_group": [
            {
                "arm_group_label": "Ranibizumab 0.3mg (12 months)", 
                "arm_group_type": "Experimental", 
                "description": "Intravitreal injection of ranibizumab 0.3mg/0.05cc"
            }, 
            {
                "arm_group_label": "Ranibizumab 0.3mg (6 months)", 
                "arm_group_type": "Active Comparator", 
                "description": "Intravitreal injection of ranibizumab 0.3mg/0.05cc"
            }
        ], 
        "brief_summary": {
            "textblock": "This is an open-label, Phase I/II study of Intravitreally administered 0.3mg ranibizumab in\n      subjects with persistent Diabetic Macular Edema (DME) after recent and frequent bevacizumab\n      (at least 2 bevacizumab intravitreal injections within 2 months prior to enrollment and at\n      least 6 bevacizumab injections within 9 months of enrollment)."
        }, 
        "brief_title": "Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetic Macular Edema", 
        "condition_browse": {
            "mesh_term": [
                "Edema", 
                "Macular Edema"
            ]
        }, 
        "detailed_description": {
            "textblock": "30 eyes will be randomized in a 1:2 ratio (Group A= 10 patients; Group B= 20 patients) Group\n      A: (\"monthly group\")- Consented patient with enrolled eye will receive 12 monthly required\n      injections of 0.3mg ranibizumab over 1 year OR Group B: (\"As needed (PRN) Group\")- Consented\n      patient with enrolled eye will receive 6 monthly required injections of 0.3mg ranibizumab\n      for 6 months, followed by as needed (PRN) dosing (required ranibizumab if DME persistent on\n      Optical Coherence Tomography (OCT) and Early Treatment Diabetic Retina Study (ETDRS) Best\n      Corrected Visual Acuity (BCVA) <20/20) for 6 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ability to provide written informed consent and comply with study assessments for the\n             full duration of the study.\n\n          -  >=18 years\n\n          -  Type I/II diabetes mellitus\n\n          -  Central-involved DME in study eye (OCT CSF >=275um on Heidelberg Spectralis spectral\n             domain OCT with evidence of intraretinal or subretinal fluid or cysts)\n\n          -  Definite retinal thickening due to diabetic macular edema involving the center of the\n             macula.\n\n          -  Media clarity, pupillary dilation and individual cooperation for adequate fungus\n             photography and fluorescein angiography.\n\n          -  Visual Acuity score in study eye <=80 and >=20 (approximate Snellen equivalent 20/25\n             to 20/400).\n\n          -  History of at least 6 intravitreal bevacizumab injections within the past 9 months\n             and 2 intravitreal bevacizumab injections within the past 2 months.\n\n          -  No history of an anti-VEGF treatment for DME in the past 3 weeks.\n\n          -  No other DME treatment for DME, other than bevacizumab, in the study eye at any time\n             in the past 3 months.\n\n          -  No history of major ocular surgery in the study eye within prior 3 months or\n             anticipated within the next six months following randomization.\n\n        Exclusion Criteria:\n\n          -  Pregnancy or lactation\n\n          -  Any other condition that the investigator believes would pose a significant hazard to\n             the subject if the investigational therapy were initiated\n\n          -  Participation in another medical investigation or trial within 30 days of\n             randomization\n\n          -  Known allergy to ranibizumab\n\n          -  Acute cardiovascular event requiring hospitalization within the past 3 months\n\n          -  Systemic anti-VEGF or pro-VEGF treatment within 3 months prior to randomization or\n             anticipated use during the study\n\n          -  Macular edema is considered to be due to a cause other than DME\n\n          -  An ocular condition is present such that, in the opinion of the investigator, visual\n             acuity loss would not improve from the resolution of macular edema\n\n          -  History of intravitreal anti-vascular endothelial growth factor (anti-VEGF) agent\n             other than bevacizumab within 9 months prior to randomization\n\n          -  History of panretinal photocoagulation within 3 months prior to randomization or\n             anticipated need for panretinal photocoagulation in the 6 months following\n             randomization\n\n          -  Yag capsulotomy performed within 1 month prior to randomization\n\n          -  External ocular infection including conjunctivitis, significant blepharitis, etc."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01845844", 
            "org_study_id": "ML28713"
        }, 
        "intervention": {
            "arm_group_label": [
                "Ranibizumab 0.3mg (12 months)", 
                "Ranibizumab 0.3mg (6 months)"
            ], 
            "description": "Group A (Arm A) will receive monthly  0.3mg/0.05cc  intravitreal injections for 12 consecutive months.\nGroup B (Arm B) will receive monthly 0.3mg/0.05cc intravitreal injections for the first six months and then PRN for the remaining 6 months per protocol specified criteria.", 
            "intervention_name": "Ranibizumab 0.3mg/0.05cc", 
            "intervention_type": "Drug", 
            "other_name": "Lucentis"
        }, 
        "intervention_browse": {
            "mesh_term": "Bevacizumab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 19, 2014", 
        "location": {
            "contact": {
                "email": "dmarcus@southeastretina.com", 
                "last_name": "Dennis M Marcus, MD", 
                "phone": "706-650-0061"
            }, 
            "contact_backup": {
                "email": "jgardner@southeastretina.com", 
                "last_name": "Jared Gardner, BS", 
                "phone": "706-650-0061"
            }, 
            "facility": {
                "address": {
                    "city": "Augusta", 
                    "country": "United States", 
                    "state": "Georgia", 
                    "zip": "30909"
                }, 
                "name": "Southeast Retina Center, PC"
            }, 
            "investigator": [
                {
                    "last_name": "Dennis M Marcus, M.D.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Harinderjit Singh, M.D.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab (ROTATE Trial)", 
        "other_outcome": [
            {
                "description": "\u25e6Mean BCVA letter changes from baseline at 1, 3, 6, 9 and 12 months", 
                "measure": "Mean BCVA letter score", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, 1, 3, 6, 9, and 12 months"
            }, 
            {
                "description": "OCT Central Subfield (CSF) thickness and macular volume mean changes from baseline at 1, 3, 6, 9 and 12 months", 
                "measure": "Mean OCT CSF thickness and macular volume", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, 1, 3, 6, 9, and 12 months"
            }
        ], 
        "overall_contact": {
            "email": "dmarcus@southeastretina.com", 
            "last_name": "Dennis M Marcus, M.D.", 
            "phone": "706-650-0061"
        }, 
        "overall_official": {
            "affiliation": "Southeast Retina Center", 
            "last_name": "Dennis M Marcus, M.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Examples include worsened acuity of greater than 30 letters, retinal detachment, endophthalmitis, cataract progression, vitreous hemorrhage, new PDR or neovascularization of the iris or angle, incidence and severity of other adverse events, as identified by physical examination, subject reporting, and changes in vital signs and will include thromboembolic events, deaths and systemic serious adverse events", 
                "measure": "Incidence of ocular and systemic adverse events will be compared between experimental and active comparator groups", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Examples include worsened acuity of greater than 30 letters, retinal detachment, endophthalmitis, cataract progression, vitreous hemorrhage, new PDR or neovascularization of the iris or angle, incidence and severity of other adverse events, as identified by physical examination, subject reporting, and changes in vital signs and will include thromboembolic events, deaths and systemic serious adverse events", 
                "measure": "Severity of ocular and systemic adverse events will be compared between experimental and active comparator groups", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01845844"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Southeast Retina Center, Georgia", 
            "investigator_full_name": "Dennis M. Marcus, M.D.", 
            "investigator_title": "Dr. Dennis M. Marcus Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Examples include  proportion of eyes with absence of fluorescein angiographic macular leakage at 12 months; proportion of eyes with unchanged, worsened, or improved fluorescein angiographic macular leakage from baseline at 1, 6 and 12 months; proportion of eyes with unchanged, worsened, or improved fundus photographic DME appearance from baseline at 1, 6 and 12 months; proportion of eyes with new vitreous hemorrhage or traction retinal detachment secondary to Proliferative Diabetic Retinopathy (PDR); proportion of eyes with progression from baseline Non-proliferative Diabetic Retinopathy (NPDR) to PDR", 
            "measure": "Efficacy of monthly and monthly followed by PRN dosing of 0.3 mg ranibizumab after persistent DME despite previous bevacizumab therapy", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "source": "Southeast Retina Center, Georgia", 
        "sponsors": {
            "collaborator": {
                "agency": "Genentech", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Southeast Retina Center, Georgia", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}